![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Rubraca Approved for Ovarian Cancer Maintenance Treatment
Rubraca Approved for Ovarian Cancer Maintenance Treatment
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
April 9, 2018
The FDA approved Clovis Oncology’s Rubraca (rucaparib) as a maintenance treatment for recurrent ovarian cancer.
The treatment is applicable for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Rubraca previously received regular approval as an earlier-line therapy based on positive data from the phase 3 clinical trial.
Upcoming Events
-
21Oct